@article{7721d4bb2dcf4471aa623bf3396a0352,
title = "A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy",
keywords = "Advanced breast cancer, Everolimus, Human epidermal growth factor receptor 2-positive, Paclitaxel, Trastuzumab resistant, mTOR inhibitor",
author = "Hurvitz, \{Sara A.\} and Florence Dalenc and Mario Campone and O'Regan, \{Ruth M.\} and Tjan-Heijnen, \{Vivianne C.\} and Joseph Gligorov and Antonio Llombart and Haresh Jhangiani and Mirshahidi, \{Hamid R.\} and Elizabeth Tan-Chiu and Sara Miao and Mona El-Hashimy and Jeremie Lincy and Tetiana Taran and Soria, \{Jean Charles\} and Tarek Sahmoud and Fabrice Andr{\'e}",
note = "Funding Information: Acknowledgments The J2101 trial was supported by Novartis Pharmaceuticals. We thank the patients, study site personnel, and the study team for their participation in the trial. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Kristin E. Larsen, PhD, ProEd Communications, Inc., for medical editorial assistance with this manuscript.",
year = "2013",
month = oct,
doi = "10.1007/s10549-013-2689-5",
language = "English",
volume = "141",
pages = "437--446",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
number = "3",
}